

## Mahajan, Vinay

---

**From:** Gupta, Ravi  
**Sent:** Wednesday, September 07, 2016 9:41 PM  
**To:** Mahajan, Vinay  
**Subject:** FW: OGD&GMA Leadership Team Organizational Announcement

You were RIGHT again!

---

**From:** McConnell, Victoria **On Behalf Of** Riva, Alessandro  
**Sent:** Wednesday, September 07, 2016 9:16 PM  
**To:** PH.O.DEV.ONCBU.ALL\_ORG; PH.O.DEV.ONCBU.CONTRACTORS.ALL\_ORG  
**Subject:** OGD&GMA Leadership Team Organizational Announcement



Dear OGD&GMA Colleagues,

I would like to announce the appointment of **Michael Branson** as Head of Oncology Biometrics function *ad interim*, reporting to me effective September 19th, 2016.

Mike joined Novartis more than 15 years ago as a Statistical Methodologist and has since taken on roles of increasing responsibilities across the GenMeds Development and Oncology Development organizations. He brings broad experience from multiple therapeutic areas, a strong background in drug development, and many years of leadership experience encompassing Biostatistics, Statistical Methodology, Modeling, Data Management and Programming to this role.

Mike succeeds **Kannan Natarajan** who has decided to pursue an opportunity outside of Novartis. Kannan's last day with the company will be September 16th. I would like to thank Kannan for his significant contributions while at Novartis over the past several years, and his strong support in the submission and approval of several Oncology assets.

Mike will also maintain his current leadership role of Full Development Biometrics within OGD&GMA. In the new role, in addition to leading the Biometrics function, he will also be the *ad interim* chair of the Biometrics, Programming and Data Management Leadership Team for OGD&GMA and assume responsibility for the GDD-GDO liaison.

Please join in me in wishing Kannan the very best in his new professional assignment, and welcoming Mike to the DLT in his *ad interim* expanded role.

Kind regards,  
Alessandro

For internal use only.

